Ropivacaine

證據等級: L5

預測適應症: 4 個

Ropivacaine: From Regional Anesthesia to Migraine Disorder

One-Sentence Summary

Ropivacaine is an amide-type local anesthetic conventionally used for regional and local nerve block anesthesia and postoperative pain control. The TxGNN model predicts it may be effective for Migraine Disorder (via nerve block procedures such as sphenopalatine and stellate ganglion block), with 4 clinical trials and 6 publications currently supporting this direction — though evidence quality is mixed and largely procedural rather than pharmacological.

Quick Overview

Item	Content
Original Indication	Local/regional anesthesia (based on known drug class; official approved indication text not available — Data Gap DG001)
Predicted New Indication	Migraine Disorder
TxGNN Prediction Score	99.65%
Evidence Level	L2
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack (Data Gap DG002). Based on established pharmacology, ropivacaine is an amide-type local anesthetic that blocks voltage-gated sodium channels to inhibit neural conduction. It is well established as a regional/local anesthetic agent, commonly delivered via nerve block, epidural, or infiltration techniques.

The mechanistic rationale for migraine is that sodium-channel blockade, when applied at specific anatomical targets — the sphenopalatine ganglion (SPG), stellate ganglion, or paraspinal/trigger-point regions — can interrupt trigeminovascular signaling and central sensitization pathways implicated in migraine pathogenesis. This is a biologically plausible mechanism supported by multiple procedural studies.

However, this repurposing candidate differs from a typical systemic-drug repurposing case: the evidence here evaluates ropivacaine as part of an interventional nerve-block procedure, not as a standalone pharmacotherapy. The rationale for the second predicted indication (migraine with brainstem aura) explicitly notes that its only supporting literature is a case report of an adverse event (Horner’s syndrome), not a treatment result, and should not be considered mechanistic support. Efficacy attribution therefore needs to be evaluated together with procedural technique, not drug pharmacology alone.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03666663	Phase 4	Completed	10	RCT of sphenopalatine ganglion (SPG) block with local anesthetic vs. placebo for migraine prevention; directly targets migraine population but severely underpowered (n=10)
NCT00680823	N/A	Completed	150	Paraspinal intramuscular ropivacaine injection evaluated for pediatric headache in an emergency department; broader headache population, not adult migraine specifically
NCT05301387	N/A	Completed	38	SPG block vs. placebo, but studies post-dural puncture headache (PDPH) rather than migraine — mechanistically related, not the same disease entity
NCT06470581	N/A	Not Yet Recruiting	78	Thoracic sympathetic ganglion block combined with Botulinum Toxin A for complex regional pain syndrome; combination design, cannot isolate ropivacaine’s effect, and not yet recruiting

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35331152	2022	Cohort	BMC Anesthesiology	Ultrasound-guided stellate ganglion block observed for migraine pain relief and quality-of-life improvement
17244105	2007	Cohort	Pain Medicine	Ropivacaine trigger-point inactivation evaluated over 12 weeks for prophylactic management of severe migraine
30043973	2019	Cohort	Headache	Sphenopalatine ganglion block evaluated for self-reported pain relief in status migrainosus
24284858	2013	Case Series	Pain Physician	Describes a revised transnasal topical SPG block technique for headache and facial pain
19145569	2009	Case Report	Revista de Neurología	Reports Horner’s syndrome as a complication following epidural analgesia — an adverse event, not efficacy evidence
17058040	2006	Case Report	The Journal of Headache and Pain	Reports migraine headache as a rare complication following cervicothoracic block

US Market Information

Ropivacaine currently has no marketing authorizations on record in the source dataset (0 licenses, market status: Not Marketed). No product/NDA table can be generated from the available evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

Note: Key warnings, contraindications, and drug-drug interaction data are currently unavailable (flagged as a Blocking data gap, DG001 — TFDA label warnings/contraindications not yet retrieved). This gap prevents the candidate from proceeding to the S1 safety initial assessment.

Conclusion and Next Steps

Decision: Hold

Rationale: The lead prediction (migraine disorder) sits at decision stage S2 with an internal recommendation of “Research Question,” reflecting L2-level evidence that is procedural (nerve block techniques) rather than direct pharmacological repurposing evidence, and includes only one directly relevant RCT (n=10, underpowered). Combined with a Blocking safety data gap (DG001) that prevents any S1 safety assessment, and zero current marketing authorizations for ropivacaine in this dataset, the candidate is not ready to proceed even under guardrails.

To proceed, the following is needed:

Retrieve TFDA/FDA package insert warnings and contraindications (DG001 — Blocking)
Retrieve detailed mechanism of action data from DrugBank (DG002)
Clarify route compatibility between ropivacaine’s current approved routes and the nerve-block/regional injection routes used in the migraine evidence (route_compatibility currently “pending”)
Adequately powered RCT confirming SPG/stellate ganglion block efficacy for migraine (current Phase 4 RCT enrolled only 10 patients)
Clarify current regulatory/market status given zero recorded licenses
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.